Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrilatazar + FOLFIRINOX in Metastatic Pancreatic Cancer
NCT04431258Phase 2Completed
- Sponsor
- AbilityPharma
- Start
- May 2021
- Primary completion
- Jan 2024
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of ibrilatazar, sponsored by AbilityPharma. Started May 2021; status: completed.
02
Drugs
ibrilatazar
Beyond the preview
Go deeper on NCT04431258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04431258.